Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Paolo Strati, MD, Koichi Takahashi, MD, Michael J. Keating, MD, Philip A. Thompson, MBBS, Christina Hinojosa, Diana Rodriguez, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Hagop M. Kantarjian, MD, William G. Wierda, MD PhD, Andrew Futreal, PhD, Alessandra Ferrajoli, MD

Blood (2018) 132 (Supplement 1): 295.

https://doi.org/10.1182/blood-2018-99-111488

Published: 2018

Journal Articles

Sustained Long-Lasting Responses after Lenalidomide Discontinuation in Patients with Chronic Lymphocytic Leukemia

Paolo Strati, MD, Alessandra Ferrajoli, MD, William G Wierda, MD PhD, Nitin Jain, MD, Philip A Thompson, MBBS, Susan M. O'Brien, MD, Katy Rezvani, MD PhD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Christina Hinojosa, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 3024.

https://doi.org/10.1182/blood.V130.Suppl_1.3024.3024

Published: 2017

Journal Articles

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Paolo Strati, MD, Philip A Thompson, MBBS, Michael Keating, MBBS, Christina Hinojosa, Diana Rodriguez, Xuemei Wang, MS, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, William G. Wierda, MD PhD, Hagop M. Kantarjian, MD, Susan Obrien, MD BA, Alessandra Ferrajoli, MD

Blood (2016) 128 (22): 4389.

https://doi.org/10.1182/blood.V128.22.4389.4389

Published: 2016

Journal Articles

Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia

Candida Vitale, MD, Maria Ciccone, MD, Christina Hinojosa, Michael Keating, MBBS, Naveen Pemmaraju, MD, Susan O'Brien, MD, William Wierda, MD PhD, Deborah A Thomas, MD, Gautam Borthakur, MD, Maro Ohanian, DO, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD

Blood (2015) 126 (23): 5292.

https://doi.org/10.1182/blood.V126.23.5292.5292

Published: 2015

Journal Articles

Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL)

Maria Ciccone, MD, Candida Vitale, Christina Hinojosa, Michael J Keating, MBBS, Naveen Pemmaraju, MD, Susan O'Brien, MD, Jan A. Burger, MD PhD, Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Paolo Strati, MD, William G. Wierda, MD PhD, Alessandra Ferrajoli, MD

Blood (2014) 124 (21): 5656.

https://doi.org/10.1182/blood.V124.21.5656.5656

Published: 2014

Journal Articles

Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study

Philip A Thompson, Michael J Keating, MBBS, Christina Hinojosa, Susan C. Smith, Naval G. Daver, MD, Nitin Jain, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, Susan O'Brien, MD, William G. Wierda, MD PhD, Hagop M. Kantarjian, MD, Alessandra Ferrajoli, MD

Blood (2014) 124 (21): 1988.

https://doi.org/10.1182/blood.V124.21.1988.1988

Published: 2014

Journal Articles

Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia

Paolo Strati, MD, Michael J. Keating, MD, Christina Hinojosa, Stefan Faderl, MD, Susan C. Smith, Susan O'Brien, MD, Jan A. Burger, MD, PhD, William G. Wierda, MD, Alessandra Ferrajoli, MD

Blood (2013) 122 (21): 4183.

https://doi.org/10.1182/blood.V122.21.4183.4183

Published: 2013

NARROW

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Sustained Long-Lasting Responses after Lenalidomide Discontinuation in Patients with Chronic Lymphocytic Leukemia

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia

Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL)

Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study

Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Combination of Lenalidomide and Rituximab in Patients with Treatment-Naïve and Relapsed Chronic Lymphocytic Leukemia: Treatment Results and Predictive Factors of Response

Sustained Long-Lasting Responses after Lenalidomide Discontinuation in Patients with Chronic Lymphocytic Leukemia

A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaïVe and Relapsed Chronic Lymphocytic Leukemia

Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia

Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL)

Lenalidomide and Rituximab in Combination As Initial Treatment of Chronic Lymphocytic Leukemia: Initial Results of a Phase II Study

Early Results Of a Phase II Study Of Lenalidomide and Rituximab As Frontline Treatment Of Patients With Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only